Skip to main content
. 2011 Jun 23;121(7):2693–2708. doi: 10.1172/JCI42946

Figure 8. Activity and content of HDL-associated PON1 in healthy subjects and patients with sCAD or ACS — effect of inhibition of PON1 on HDL-associated MDA content and phosphorylation of PKCβII at Ser660.

Figure 8

(A) Paraoxonase and (B) arylesterase activities of HDL-associated PON1 isolated from healthy subjects and patients with sCAD or ACS, as measured by UV spectrophotometry (n = 25 per group). (C) PON1 content in HDL isolated from healthy subjects and patients with sCAD or ACS was determined by Western blot analysis (n = 25 per group). (D) Effect of the specific PON1 inhibitor hydroxyquinoline (HQ, 200 μM) on protein-bound MDA content and (E) MDA-lysine adducts in HDL, as detected by spectrophotometry and mass-spectrometry analysis, respectively (n = 4–6 per group). (F) Effect of HDL pretreated with the PON1 inhibitors HQ or EDTA (5 mM) on phosphorylation of PKCβII at Ser660 was detected by Western blot analysis (n = 8–10 per group).